|Opexa Therapeutics, Inc.|
2635 Technology Forest Boulevard
United States - Map
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
|Mr. Neil K. Warma ,
Chief Exec. Officer, Pres, Sec. and Director
|Mr. Karthik Radhakrishnan CFA,
Chief Financial Officer and Principal Accounting Officer
|Mrs. Donna R. Rill ,
Chief Devel. Officer
|Dr. Donald Healey Ph.D.,
VP of Scientific Devel.
|Mr. Kenny Frazier ,
VP of Clinical Devel. & Regulatory Affairs
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|